[HTML][HTML] Quinazoline derivatives as potential therapeutic agents in urinary bladder cancer therapy

P Wdowiak, J Matysiak, P Kuszta, K Czarnek… - Frontiers in …, 2021 - frontiersin.org
Derivatives of quinazolines constitute a large group of chemicals with a wide range of
biological properties. The character of quinazolines depends mostly on the properties of the …

Quinazoline compounds for antitumor treatment

GI Solyanik - Experimental oncology, 2019 - exp-oncology.com.ua
Quinazolines are among the most useful heterocyclic compounds due to their diverse
chemical reactivity and a wide range of biological activity. Despite a large number of …

[HTML][HTML] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study

B Gieszer, Z Megyesfalvi, V Dulai, J Papay… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Although lung adenocarcinoma (LADC) with sensitizing mutations of the
epidermal growth factor receptor (EGFR) is highly sensitive to EGFR tyrosine kinase …

[HTML][HTML] Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update

RR Naik, AK Shakya - Frontiers in Pharmacology, 2023 - frontiersin.org
Protein kinases are enzymes that transfer phosphate to protein, resulting in the modification
of the protein. The human genome encodes approximately 538 kinases. Kinases play a role …

[HTML][HTML] ANGPTL4 regulates lung adenocarcinoma pyroptosis and apoptosis via NLRP3\ASC\Caspase 8 signaling pathway to promote resistance to gefitinib

Y Fang, X Li, H Cheng, L Zhang, J Hao - Journal of Oncology, 2022 - hindawi.com
Background. Prior research has identified ANGPTL4 as a key player in the control of the
body's lipid and glucose metabolism and a contributor to the onset of numerous …

Cancer management by tyrosine kinase inhibitors: efficacy, limitation, and future strategies

VWT Ho, HY Tan, N Wang, Y Feng - Tyrosine Kinases as …, 2019 - books.google.com
Tyrosine kinase inhibitors are taking up an increasingly significant role in treating cancers.
There are different types of TKIs currently used in clinical settings. However, TKI-associated …

Target Aksi Obat Gefitinib Pada Reseptor Tirosin Kinase Terhadap Penyakit Kanker Paru

AR Kusumawardhani, A Yuniar… - Jurnal …, 2022 - journal.universitaspahlawan.ac.id
Kanker paru merupakan tumor ganas di paru-paru yang asalnya dari epitel saluran nafas.
Faktor penyebab kanker paru adalah mutasi gen pada jalur sinyal Epidermal Growth Factor …

Targeting the tumor-associated macrophages for 'Normalizing'cancer

J Kzhyshkowska, E Grigoryeva, I Larionova - … Complex Diseases: Network …, 2020 - Springer
Macrophages are a major component of the leukocyte infiltrate of tumor microenvironment.
Their involvement in tumor progression was demonstrated for many cancers, including …

[PDF][PDF] Efikasi Terapi Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKIs) pada Kanker Paru

F Wulandari, W Utami, E Rohana, WR Prabhata - 2021 - doc-pak.undip.ac.id
Adanya identifikasi Epidermal Growth Factor Receptor (EGFR) sebagai target molekular
mempengaruhi model terapi kanker paru jenis Non-Small Cell Lung Cancer (NSCLC) …

[PDF][PDF] EVALUATION OF PREDICTIVE AND PROGNOSTIC BIOMARKERS IN THORACIC MALIGNANCIES

B Gieszer - 2022 - repo.lib.semmelweis.hu
In recent decades, with the accessibility and application of different anti-tumor treatments,
the survival of cancer patients has improved. Nevertheless, the overall survival rate in …